Avantor (NYSE:AVTR) Price Target Cut to $25.00 by Analysts at Wells Fargo & Company

Avantor (NYSE:AVTR - Get Free Report) had its target price lowered by research analysts at Wells Fargo & Company from $28.00 to $25.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has an "overweight" rating on the stock. Wells Fargo & Company's price objective points to a potential upside of 37.79% from the company's previous close.

AVTR has been the subject of a number of other reports. Stifel Nicolaus reduced their price target on shares of Avantor from $28.00 to $26.00 and set a "buy" rating for the company in a research report on Monday. Raymond James reduced their target price on Avantor from $29.00 to $26.00 and set an "outperform" rating for the company in a research report on Tuesday, January 21st. Barclays lowered their price target on Avantor from $26.00 to $23.00 and set an "overweight" rating on the stock in a report on Monday. UBS Group reissued a "neutral" rating and set a $25.00 price objective (down previously from $29.00) on shares of Avantor in a report on Friday, January 17th. Finally, Robert W. Baird lowered their target price on shares of Avantor from $27.00 to $26.00 and set an "outperform" rating on the stock in a research note on Monday, October 28th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $26.15.

Avantor Price Performance

AVTR traded up $0.09 during trading on Monday, reaching $18.14. 3,754,691 shares of the company were exchanged, compared to its average volume of 5,347,450. Avantor has a 12-month low of $17.90 and a 12-month high of $28.00. The company's 50-day moving average is $21.57 and its two-hundred day moving average is $23.35. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. The company has a market cap of $12.35 billion, a price-to-earnings ratio of 39.46, a P/E/G ratio of 3.87 and a beta of 1.28.

Avantor (NYSE:AVTR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same period in the prior year, the business earned $0.22 EPS. Research analysts forecast that Avantor will post 0.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. MassMutual Private Wealth & Trust FSB grew its holdings in Avantor by 99.5% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company's stock worth $26,000 after acquiring an additional 625 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Avantor by 106.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company's stock worth $34,000 after purchasing an additional 830 shares during the period. UMB Bank n.a. bought a new stake in shares of Avantor in the third quarter worth about $49,000. Global Retirement Partners LLC increased its holdings in Avantor by 76.7% during the 4th quarter. Global Retirement Partners LLC now owns 2,459 shares of the company's stock valued at $52,000 after purchasing an additional 1,067 shares during the period. Finally, Nisa Investment Advisors LLC raised its position in Avantor by 69.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company's stock valued at $53,000 after purchasing an additional 835 shares during the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.